Symphogen Competitors and Similar CompaniesClear all

Symphogen's competitors and similar companies include Epizyme, Janssen, Chugai Pharmaceutical and Achilles Therapeutics.

	Symphogen Symphogen is a biotech company focused on oncology and immuno-oncology.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	Janssen Janssen is a company providing prescription pharmaceutical products.	Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.	Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
Founding Date	Founding Date 2000	Founding Date 2007	Founding Date 1953	Founding Date 1925	Founding Date 2016
Type	Type Private	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations Ballerup, DK HQ Somerville, US	Locations Cambridge, US HQ	Locations Raritan, US HQ Vienna, AT Prague, CZ Espoo, FI Budapest, HU Oslo, NO Belgrade, RS see more	Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more	Locations London, GB HQ Stevenage, GB
Employees	Employees 196	Employees 20364% increase	Employees 17,3684% decrease	Employees 7,778	Employees 695% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 250.8 m	Valuation ($) N/A	Valuation ($) 78.7 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) ¥1.3t (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $10.5m (FY, 2021)	Cost of goods N/A	Cost of goods ¥363.7b (FY, 2025)	Cost of goods N/A
Net income	Net income N/A	Net income ($251.1m) (FY, 2021)	Net income N/A	Net income ¥434b (FY, 2025)	Net income ($69.7m) (FY, 2023)
Funding
Total funding raised	Total funding raised $ 387.2m	Total funding raised $ 51.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 138.1m